Prostate cancer is one of the most common cancers in men worldwide, and for many patients, hormones fuel its growth. Hormone therapy — also called androgen deprivation therapy — works by cutting off the hormones that feed prostate cancer cells. It is a cornerstone of treatment for advanced disease, and its role is expanding. As prostate cancer rates rise, the hormone therapy market is growing.

Hormone therapy works by reducing testosterone levels or blocking its effects. Options include GnRH agonists and antagonists, antiandrogens, and newer agents like abiraterone and enzalutamide. These treatments can slow cancer growth, relieve symptoms, and extend survival. They are used in advanced disease, after surgery or radiation, and increasingly in earlier stages. Demand is driven by prostate cancer prevalence, aging populations, and new drug approvals. The Prostate Cancer Hormone Therapy Market reflects this growth.

For patients, hormone therapy can mean longer life and better quality of life. For providers, it means more options. For manufacturers, it means a growing market. As research advances, hormone therapy will remain essential.

People Also Ask

What is prostate cancer hormone therapy?
It is treatment that reduces or blocks hormones that fuel prostate cancer growth.

Who needs hormone therapy?
Patients with advanced prostate cancer, and increasingly those with earlier-stage disease, may benefit.

Tags: #ProstateCancer #HormoneTherapy #ADT #Oncology #MensHealth #PatientCare